不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
滤泡性淋巴瘤的当前与未来治疗
英文原题：Current and future therapies for follicular lymphoma.
查看英文原题
Current and future therapies for follicular lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
滤泡性淋巴瘤（FL）是一种惰性的、生发中心B细胞来源的淋巴系统肿瘤，近年来治疗方面的进展已显著改善了患者的生存。然而，FL仍然是一种不可治愈且异质性强的疾病，部分患者会出现早期疾病进展、组织学转化或治疗相关毒性的高风险。此外，FL是一种持续复发的疾病，随着后续每一线治疗，缓解率和疾病控制间期均逐渐降低。在本综述中，我们探讨了复发/难治性FL的当前治疗格局及在研的有前景的疗法，重点介绍了每种治疗的疗效和潜在风险。我们从真实世界的视角阐述了FL患者未被满足的需求。在研的新型治疗方法为临床医生治疗复发/难治性FL提供了广泛的选择。需要采取细致入微的方法来满足个体患者的需求，综合考虑每种治疗方案的获益与风险以及患者的偏好。
展开英文摘要原文
Follicular lymphoma (FL) is an indolent, germinal center B cell-derived lymphoid neoplasm, for which recent advances in treatment have substantially improved patient survival.
However, FL remains an incurable and heterogeneous disease, with groups of patients experiencing early disease progression, histologic transformation, or a high risk of treatment-related toxicity.
Additionally, FL is a continually relapsing disease, and response rates and disease-control intervals decrease with each subsequent line of therapy. In this review, we explore the current treatment landscape for relapsed or refractory FL and promising therapies in development, highlighting the efficacy and potential risks of each treatment.
We provide a real-world perspective on the unmet needs of patients with FL. Novel therapeutic approaches in development offer a wide array of options for clinicians when treating relapsed or refractory FL. A nuanced approach is required to address the needs of individual patients, taking into consideration both the risks and benefits of each treatment option, as well as patient preferences.
论文信息
- 作者
- Zinzani PL、Muñoz J、Trotman J
- 第一作者单位
- IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia Seràgnoli, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.Italy
- 通讯作者单位
- Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA. munoz.javier@mayo.edu.United States
- 文献类型
- 综述
- 期刊
- Experimental hematology & oncology2024 Aug 22
- 原文标识
- PubMed 39175100 · DOI 10.1186/s40164-024-00551-1
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →